文献速递妇科

高危早期卵巢癌术前及化疗前CA-125水平——一项NRG/GOG研究

Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer - An NRG/GOG study.
PubMed 文献 · Gynecol Oncol · 2023-12-21

本研究纳入427例高危早期上皮性卵巢癌患者,分析术前及化疗前CA-125的临床意义。化疗前CA-125升高独立预测更差的无复发生存(HR=2.13)和总生存(HR=1.99),而术前CA-125无预后价值。

要点

  • 高危早期卵巢癌患者中79%术前CA-125升高,中位值103 U/mL。
  • 化疗前CA-125升高者无复发生存87% vs 75%,总生存88% vs 82%。
  • 术前CA-125对无复发生存(p=0.699)和总生存(p=0.701)无预后意义。

核心结论

  • 化疗前CA-125升高与更差的无复发生存和总生存独立相关,而术前CA-125无预后价值。

研究设计与样本

  • 一项III期试验纳入427例高危早期上皮性卵巢癌患者,均接受化疗,采用Kaplan-Meier法和Cox比例风险模型分析。

主要发现

  • 213例有术前CA-125数据的患者中79%升高,中位值103 U/mL;肿瘤≤10、11-15和>15 cm者术前CA-125中位值分别为62、131和158 U/mL(p=0.002)。
  • 350例有化疗前CA-125数据的患者中69%高于35 U/mL,中位值65 U/mL;年龄、种族、分期、细胞类型和分级与手术前后CA-125水平不相关。
  • 多因素分析显示化疗前CA-125升高独立预测更差的无复发生存(HR=2.13,95%CI:1.23-3.69;p=0.007)和总生存(HR=1.99,95%CI:1.10-3.59;p=0.022)。
  • 与CA-125正常者相比,化疗前CA-125升高者无复发生存更低(87% vs 75%;p=0.007),总生存更低(88% vs 82%;p=0.02)。
  • 术前CA-125对无复发生存(p=0.699)和总生存(p=0.701)无预后意义。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine clinical significance of preoperative and pre-chemotherapy CA-125 in high-risk early-stage epithelial ovarian cancer patients. METHODS: All patients with stage IA/IB and grade 3, stage IC, clear cell, or completed resected stage II cancer were enrolled in a phase III trial and treated with chemotherapy. Kaplan-Meier method and Cox proportional hazards model were used for statistical analyses. RESULTS: 427 patients with high-risk early-stage ovarian cancer were enrolled. Of 213 patients with preoperative CA-125 data, 79% had elevated CA-125. Median preoperative CA-125 level was 103 U/mL. Patients with ≤10, 11-15, and > 15 cm tumors had median preoperative CA-125 levels of 62, 131 and 158 U/mL, respectively (p = 0.002). For the 350 patients with data for pre-chemotherapy CA-125 level, 69% had elevated pre-chemotherapy CA-125 above 35 U/mL with median value of 65 U/mL. However, age, race, stage, cell type and grade of disease were not correlated with CA-125 levels before and after surgery. On multivariate analysis, elevated pre-chemotherapy CA-125 independently predicted worse recurrence-free survival (HR = 2.13, 95% CI: 1.23-3.69; p = 0.007) and overall survival (HR = 1.99, 95% CI: 1.10-3.59; p = 0.022) after adjusting for age, stage, cell type and grade of disease. Compared to those with normal CA-125, patients with elevated pre-chemotherapy CA-125 had lower recurrence-free survival (RFS, 87% vs. 75%; p = 0.007) and overall survival (OS, 88% vs. 82%; p = 0.02). However, preoperative CA-125 was not prognostic of RFS (p = 0.699) or OS (p = 0.701). CONCLUSIONS: Preoperative CA-125 was elevated in nearly 80% of high-risk early-stage ovarian cancer patients. Pre-chemotherapy CA-125 was associated with recurrence-free and overall survival; however, preoperative CA-125 was not prognostic.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Chan JK, Tian C, Kesterson JP, et al. Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer - An NRG/GOG study. Gynecol Oncol. 2023. PMID: 38134754. doi:10.1016/j.ygyno.2023.12.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。